Latest Period
Q4 2025
Security Snapshot
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) Institutional Ownership
CUSIP: 482929106
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
51
Shares (Excl. Options)
17,996,162
Price
$8.44
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KLRS on Nasdaq
- Shares outstanding
- 22,927,577
- Price per share
- $6.31
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 17,996,162
- Total reported value
- $151,883,912
- % of total 13F portfolios
- 0%
- Share change
- +4,531,984
- Value change
- +$39,427,360
- Number of holders
- 51
- Price from insider filings
- $6.31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 482929106.
- 51 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 51 to 6 between Q4 2025 and Q1 2026.
- Reported value moved from $151,883,912 to $1,529,270.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 51 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 482929106?
CUSIP 482929106 identifies KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482929106:
Significant Owners of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 56% | -7.7% | $90,804,603 | +$10,553,555 | 12,953,581 | +13% | Srinivas Akkaraju | 22 Dec 2025 |
| RTW INVESTMENTS, LP | 5.7% | $12,714,000 | 1,300,000 | RTW Investments, LP | 31 Dec 2025 | |||
| GILEAD SCIENCES, INC. | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | |||
| Invus Global Management, LLC | 1.5% | $754,533 | 282,586 | Invus Public Equities, L.P. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 1.1% | $1,315,201 | 201,718 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 31 Dec 2025, 51 institutional investors reported holding 17,996,162 shares of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS). This represents 78% of the company’s total 22,927,577 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 56% | 12,948,081 | +13% | 11% | $109,281,804 |
| RTW INVESTMENTS, LP | 5.7% | 1,300,000 | 0.11% | $10,972,000 | |
| Paradigm Biocapital Advisors LP | 3.1% | 700,000 | 0.16% | $5,908,000 | |
| Siren, L.L.C. | 1.9% | 435,798 | +37% | 0.11% | $3,678,135 |
| Alyeska Investment Group, L.P. | 1.8% | 403,551 | 0.01% | $3,402,109 | |
| Ikarian Capital, LLC | 1.6% | 360,000 | 0.4% | $3,038,401 | |
| VANGUARD GROUP INC | 1.3% | 292,790 | +44% | 0% | $2,471,147 |
| Kalehua Capital Management LLC | 0.61% | 139,901 | 0% | 1.2% | $1,180,764 |
| ADAR1 Capital Management, LLC | 0.44% | 100,000 | 0.06% | $844,000 | |
| Woodline Partners LP | 0.44% | 100,000 | -59% | 0% | $844,000 |
| WHI TRUST Co LLC | 0.43% | 97,493 | 0% | 0.63% | $822,841 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.4% | 92,261 | 0.02% | $778,683 | |
| RAYMOND JAMES FINANCIAL INC | 0.39% | 88,436 | 0% | $746,400 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 87,751 | -22% | 0% | $740,618 |
| Redmile Group, LLC | 0.36% | 82,955 | 0% | 0.05% | $700,140 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.36% | 82,647 | +28% | 0% | $697,599 |
| 683 Capital Management, LLC | 0.35% | 80,590 | 0.06% | $680,180 | |
| MARSHALL WACE, LLP | 0.32% | 72,876 | +416% | 0% | $615,074 |
| Propel Bio Management, LLC | 0.18% | 42,053 | 0.3% | $354,927 | |
| Fortis Capital Advisors, LLC | 0.17% | 40,000 | 0% | 0.05% | $337,600 |
| Belpointe Asset Management LLC | 0.17% | 40,000 | 0% | 0.01% | $337,600 |
| BlackRock, Inc. | 0.17% | 38,454 | -4.8% | 0% | $324,552 |
| GOLDMAN SACHS GROUP INC | 0.15% | 34,303 | +53% | 0% | $289,518 |
| JANE STREET GROUP, LLC | 0.14% | 33,114 | 0% | $279,482 | |
| OMERS ADMINISTRATION Corp | 0.13% | 30,000 | 0% | $253,200 |
Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 265,038 | $1,529,270 | +$388,621 | $5.77 | 6 |
| 2025 Q4 | 17,996,162 | $151,883,912 | +$39,427,360 | $8.44 | 51 |
| 2025 Q3 | 13,222,873 | $76,428,251 | +$1,455,559 | $5.78 | 31 |
| 2025 Q2 | 13,362,268 | $35,677,274 | -$2,639,077 | $2.67 | 29 |
| 2025 Q1 | 13,874,350 | $111,411,096 | +$111,410,076 | $8.03 | 31 |